Digital Health Market 2026: Telehealth Persistence, AI Regulation, and the Rise of Platform Gatekeepers

The global digital health market is projected to reach $946.04 billion by 2030, growing at a compound annual growth rate (CAGR) of 22.2% from $288.55 billion in 2024, according to Grand View Research. These headline numbers suggest a booming industry, but a closer examination reveals a more nuanced picture. While the market is expanding rapidly, the real story lies in the strategic battle between entrenched infrastructure incumbents and agile startups, a battle being fought over data ownership, regulatory moats, and platform dependencies. This report dissects five transformative forces shaping the digital health landscape as we approach 2026: the enduring adoption of telehealth, a record-breaking wave of FDA-authorized AI medical devices, the near-duopoly of electronic health record (EHR) vendors, a rebounding startup funding cycle, and an accelerating demand for health IT professionals. Together, these forces are bifurcating the industry into two camps: those who own the platform and those who must navigate it.

[IMAGE: A bar chart showing the market growth trajectory from 2024 to 2030, with annotations for key inflection points such as telemedicine regulations, FDA AI approvals, and EHR market share shifts.]

Telehealth: The 63-Fold Spike That Stayed

In 2019, Medicare fee-for-service beneficiaries logged approximately 840,000 telehealth visits. One year later, that number exploded to 52.7 million — a staggering 63-fold increase driven by pandemic-era emergency waivers. Critics at the time predicted a sharp post-pandemic reversion to in-person care. But the data tells a different story. According to the U.S. Department of Health and Human Services (HHS), 25% of Medicare fee-for-service users still utilized telehealth in 2024. This plateau is not a decline; it represents a structural shift in care delivery.

The digital health market has absorbed telehealth as a permanent channel, not a temporary convenience. This persistence drives demand for robust digital infrastructure, deep EHR integration, and sustainable reimbursement models. Virtual-first primary care providers, remote patient monitoring platforms, and telepsychiatry services are now standard offerings. The challenge for health systems is no longer whether to offer telehealth, but how to seamlessly embed it into existing workflows. This has created a lucrative niche for startups that can solve interoperability friction — a niche that is increasingly dominated by partnerships with the EHR giants that control the underlying data.

[IMAGE: Line graph showing Medicare fee-for-service telehealth visits from 2019 to 2024, with a steep rise in 2020 and a stable plateau around 13–14 million quarterly visits through 2024.]

AI/ML Medical Devices: FDA Opens the Floodgates

The U.S. Food and Drug Administration (FDA) has dramatically accelerated its authorization of artificial intelligence and machine learning (AI/ML)-enabled medical devices. As of December 2024, the agency had authorized 1,016 such devices, with a record 168 approved in a single year — more than double the 2021 total. This regulatory acceleration signals growing confidence in algorithmic safety and efficacy, but it also raises urgent questions about post-market surveillance, algorithm drift, and long-term clinical validation.

The device categories span radiology (the dominant segment, accounting for over 70% of approvals), cardiology, neurology, and increasingly, clinical decision support. Startups such as NeuroStory, which uses AI for brain health diagnostics, and MEDIX-CARE, focused on care coordination and predictive analytics, are leveraging this regulatory tailwind. Yet, these companies must navigate an evolving FDA framework that is still grappling with how to manage continuous learning algorithms. The 2024 guidance on predetermined change control plans offers some clarity, but the burden of demonstrating ongoing safety and effectiveness remains a significant barrier to entry — one that favors well-capitalized incumbents with existing regulatory affairs infrastructure.

[IMAGE: Timeline of FDA AI/ML device authorizations by year from 2018 to 2024, highlighting the sharp increase since 2020 with a 168-device record in 2024. Include a breakdown by specialty (e.g., radiology, cardiology).]

The EHR Duopoly: Gatekeepers of Digital Health Data

If data is the lifeblood of digital health, then EHR vendors are the circulatory system. As of 2021 (the latest comprehensive data from the Office of the National Coordinator for Health IT), Epic Systems controlled 32.8% of U.S. hospital beds, and Oracle Cerner held 23.2%, together commanding a 56% market share. These platforms function as the operating system of healthcare — any digital health tool that needs to exchange patient data, schedule appointments, or trigger clinical alerts must integrate with one or both. This economic moat is deep and expanding.

The cost of interoperability is non-trivial. Epic's App Orchard and Cerner's code-based APIs have opened some doors, but the integration process remains expensive, time-consuming, and often subject to vendor-specific data models. For digital health startups — especially those offering niche point solutions — the choice is binary: partner with the duopoly or build a standalone product that risks being sidelined by health systems' procurement preferences. Alternative vendors like MEDITECH (16.4%) and CPSI (6.7%) hold regional or niche positions but lack the scale to disrupt the duopoly's grip.

This concentration has implications for the entire digital health market. Venture-backed startups that fail to secure EHR integration early often struggle with adoption. Conversely, startups that become "must-have" extensions of the Epic or Cerner ecosystem can achieve rapid scaling. The gatekeeper power of these platforms will define the competitive dynamics of the industry through 2026 and beyond.

[IMAGE: Pie chart of U.S. hospital EHR vendor market share in 2021, with Epic (32.8%) and Cerner (23.2%) dominant, followed by MEDITECH (16.4%), CPSI (6.7%), and others. Note: Oracle acquired Cerner in 2022, further consolidating the market.]

Startup Ecosystem: $14.2B in 2025 — A Resurgence or Bubble?

After a funding trough in 2022 and 2023, the U.S. digital health startup ecosystem staged a comeback. According to Rock Health, startups raised $14.2 billion across 482 deals in 2025, a 35% year-over-year increase. This resurgence has been fueled by a few mega-rounds — including a $1.2 billion raise by a value-based care platform — but also by a steady flow of early-stage investments in AI-enabled diagnostics, decentralized clinical trials, and mental health applications.

Yet the data warrants cautious interpretation. The aggregate figure masks a widening gap between the top-tier startups and the rest. Series A and B rounds are taking longer to close, and valuations have normalized after the 2021 frenzy. The rebound of $14.2B in 2025 is still below the 2021 peak of $29.1B. Investors are increasingly focused on unit economics, revenue visibility, and defensibility — criteria that favor startups with data moats or platform-level partnerships. The so-called "resurgence" may be less a new boom and more a recalibration, where capital flows to a smaller cohort of companies that can demonstrate sustainable integration into the healthcare delivery system.

Furthermore, the funding landscape is shifting geographically. While California and Massachusetts remain dominant, emerging hubs in Texas, Florida, and the Midwest are attracting attention, particularly for startups targeting rural health and chronic care management. The digital health market is no longer a coastal story.

[IMAGE: Bar chart showing U.S. digital health startup annual funding from 2019 to 2025 (Rock Health), with a peak at $29.1B in 2021, a trough at $10.5B in 2023, and a recovery to $14.2B in 2025. Overlay deal count trend line.]

The Workforce Squeeze: Health IT Jobs Surge 15%

The demand for skilled health IT professionals has never been higher. The U.S. Bureau of Labor Statistics projects a 15% growth rate for health information technologists and medical registrars through 2032, nearly three times the average for all occupations. This growth is driven by the same forces reshaping the digital health market: the need to integrate telehealth platforms, manage AI algorithm deployments, comply with evolving data interoperability standards (such as the Information Blocking Rule and FHIR APIs), and secure increasingly targeted healthcare data.

Health systems and digital health startups alike are competing for a limited talent pool. Roles in clinical informatics, data engineering, and cybersecurity command premium salaries. This labor bottleneck could slow adoption of new technologies — particularly for smaller health systems and startups that cannot match the compensation packages of Epic, Oracle, or large hospital chains. The 15% growth forecast is a double-edged sword: it reflects robust demand but also signals a structural constraint that could reshape the pace of digitization.

[IMAGE: Infographic showing projected job growth for health IT professionals (15%) vs. average for all occupations (5%), with icons for roles such as clinical informaticist, data engineer, and cybersecurity analyst.]

Conclusion: The Bifurcation Ahead

The $946 billion digital health market of 2030 will not be a level playing field. Our analysis points to a bifurcating industry. On one side, infrastructure incumbents — the EHR duopoly, established health systems, and AI platforms with FDA-cleared algorithms — are building economic moats through data control, regulatory expertise, and labor dominance. On the other side, nimble startups must navigate platform dependencies, data integration hurdles, and a funding environment that rewards sound unit economics over growth-at-all-costs.

Telehealth persistence ensures that digital interactions are here to stay, but their value is unlocked only through seamless integration with the EHR backbone. The flood of FDA-authorized AI/ML devices signals regulatory confidence, but the burden of post-market surveillance will separate the durable from the ephemeral. The startup funding rebound offers liquidity, but it flows to companies that can demonstrate defensibility — often through partnerships with the very gatekeepers they might wish to disrupt.

For investors, policymakers, and healthcare leaders, the next decade will be defined not by raw growth, but by strategic positioning. Those who control the platform — the data, the regulatory pathway, and the clinical workflow — will capture the lion's share of value. Those who do not must choose their alliances wisely. The future of digital health is not merely digital; it is politicized, regulated, and platformized.

[IMAGE: A futuristic digital health ecosystem: a glowing transparent human anatomy overlaid with connected data nodes, AI chips, and telehealth icons, with a split screen showing a hospital EHR dashboard on one side and a startup innovation lab on the other. Blue and green neon tones, no text or watermark, dynamic composition.]